Literature DB >> 20052524

Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients.

Roberto Bizzotto1, Stefano Zamuner, Giuseppe De Nicolao, Mats O Karlsson, Roberto Gomeni.   

Abstract

Hypnotic drug development calls for a better understanding of sleep physiology in order to improve and differentiate novel medicines for the treatment of sleep disorders. On this basis, a proper evaluation of polysomnographic data collected in clinical trials conducted to explore clinical efficacy of novel hypnotic compounds should include the assessment of sleep architecture and its drug-induced changes. This work presents a non-linear mixed-effect Markov-chain model based on multinomial logistic functions which characterize the time course of transition probabilities between sleep stages in insomniac patients treated with placebo. Polysomnography measurements were obtained from patients during one night treatment. A population approach was used to describe the time course of sleep stages (awake stage, stage 1, stage 2, slow-wave sleep and REM sleep) using a Markov-chain model. The relationship between time and individual transition probabilities between sleep stages was modelled through piecewise linear multinomial logistic functions. The identification of the model produced a good adherence of mean post-hoc estimates to the observed transition frequencies. Parameters were generally well estimated in terms of CV, shrinkage and distribution of empirical Bayes estimates around the typical values. The posterior predictive check analysis showed good consistency between model-predicted and observed sleep parameters. In conclusion, the Markov-chain model based on multinomial logistic functions provided an accurate description of the time course of sleep stages together with an assessment of the probabilities of transition between different stages.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20052524     DOI: 10.1007/s10928-009-9148-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  The relationship between slow-wave activity, body temperature, and cardiac activity during nighttime sleep.

Authors:  H J Burgess; A L Holmes; D Dawson
Journal:  Sleep       Date:  2001-05-01       Impact factor: 5.849

2.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

3.  Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.

Authors:  Sandra Giménez; Susana Clos; Sergio Romero; Eva Grasa; Adelaida Morte; Manuel J Barbanoj
Journal:  Psychopharmacology (Berl)       Date:  2007-01-05       Impact factor: 4.530

Review 4.  Diagnosing model diagnostics.

Authors:  M O Karlsson; R M Savic
Journal:  Clin Pharmacol Ther       Date:  2007-07       Impact factor: 6.875

5.  An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.

Authors:  Milton Erman; David Seiden; Gary Zammit; Stephen Sainati; Jeffrey Zhang
Journal:  Sleep Med       Date:  2005-11-23       Impact factor: 3.492

6.  Modeling sleep data for a new drug in development using markov mixed-effects models.

Authors:  Maria C Kjellsson; Daniele Ouellet; Brian Corrigan; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-06-17       Impact factor: 4.200

7.  Simulation of human hypnograms using a Markov chain model.

Authors:  B Kemp; H A Kamphuisen
Journal:  Sleep       Date:  1986       Impact factor: 5.849

8.  A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.

Authors:  M O Karlsson; R C Schoemaker; B Kemp; A F Cohen; J M van Gerven; B Tuk; C C Peck; M Danhof
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

Review 9.  Insomnia: epidemiology, characteristics, and consequences.

Authors:  Thomas Roth; Timothy Roehrs
Journal:  Clin Cornerstone       Date:  2003

Review 10.  Insomnia in the geriatric patient.

Authors:  Alon Y Avidan
Journal:  Clin Cornerstone       Date:  2003
View more
  14 in total

1.  Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.

Authors:  Roberto Bizzotto; Stefano Zamuner; Enrica Mezzalana; Giuseppe De Nicolao; Roberto Gomeni; Andrew C Hooker; Mats O Karlsson
Journal:  AAPS J       Date:  2011-06-21       Impact factor: 4.009

2.  Modeling sleep data for a new drug in development using markov mixed-effects models.

Authors:  Maria C Kjellsson; Daniele Ouellet; Brian Corrigan; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-06-17       Impact factor: 4.200

3.  A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat.

Authors:  C Diack; O Ackaert; B A Ploeger; P H van der Graaf; R Gurrell; M Ivarsson; D Fairman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-09-10       Impact factor: 2.745

4.  Quasi-supervised scoring of human sleep in polysomnograms using augmented input variables.

Authors:  Farid Yaghouby; Sridhar Sunderam
Journal:  Comput Biol Med       Date:  2015-01-23       Impact factor: 4.589

5.  Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Authors:  Simon Frey; Roland Linder; Georg Juckel; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2013-02-19

6.  Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model.

Authors:  C Steven Ernest; Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-12       Impact factor: 2.745

7.  Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements.

Authors:  V Pilla Reddy; K J Petersson; A A Suleiman; A Vermeulen; J H Proost; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

8.  Comparisons of Analysis Methods for Proof-of-Concept Trials.

Authors:  K E Karlsson; C Vong; M Bergstrand; E N Jonsson; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-16

9.  Chronic escitalopram treatment attenuated the accelerated rapid eye movement sleep transitions after selective rapid eye movement sleep deprivation: a model-based analysis using Markov chains.

Authors:  Diána Kostyalik; Szilvia Vas; Zita Kátai; Tamás Kitka; István Gyertyán; Gyorgy Bagdy; László Tóthfalusi
Journal:  BMC Neurosci       Date:  2014-11-19       Impact factor: 3.288

10.  A multi-state spatio-temporal Markov model for categorized incidence of meningitis in sub-Saharan Africa.

Authors:  L Agier; M Stanton; G Soga; P J Diggle
Journal:  Epidemiol Infect       Date:  2012-09-21       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.